Biotech focused on the treatment of cancer and inflammatory diseases via Adenosine Receptors (A2A/A2B Agonists and Antagonists).

LNC has patented compounds which have proven to be effective in the treatment of cancer and inflammatory diseases.

Signed Material Transfer Agreement for sports injury in May '16. In active discussions regarding Material Transfer Agreement with multiple pharma companies for cancer and sickle cell disease.